Eliminating Narcotic Prescriptions From Outpatient Minimally Invasive Gynecologic Surgery (eNARCOS)
Primary Purpose
Pain, Postoperative, Opioid Use
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
prescription for regular acetaminophen and naproxen
prescription for regular acetaminophen , naproxen and dilaudid
Sponsored by
About this trial
This is an interventional prevention trial for Pain, Postoperative focused on measuring Gynecology, Minimally invasive surgery, Laparoscopy
Eligibility Criteria
Inclusion Criteria:
- Women undergoing elective outpatient gynecologic laparoscopy
- Able to provide informed consent
- Planned for same day discharge
Exclusion Criteria:
- Chronic pain conditions including, but not limited to: chronic pelvic pain, fibromyalgia, connective tissue disorders, migraines on medication, severe osteoarthritis, sciatica, degenerative disk disease
- Regular use of analgesia or narcotics. Defined as use of pain medication on most days of the week, most weeks of the month
- History of substance abuse (opioid addiction, IV drug use, etc.)
- Known depression or anxiety conditions with or without medication
- Eastern Cooperative Oncology Group (ECOG) performance status 3 or greater
- Current or recent use of pain modulators such as pregabalin or gabapentin (one month pre-operatively).
- Allergy or contraindication to acetaminophen or NSAIDs or hydromorphone/narcotics
- Intraoperative complications :
- Conversion to laparotomy or mini-laparotomy > 4 cm
- Intra-operative gastrointestinal or urologic injury
- Intra-operative hemorrhage or need for blood transfusion
- Need for admission
Sites / Locations
- McGill University Health CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Acetaminophen and naproxen only arm
Acetaminophen, naproxen and dilaudid arm
Arm Description
Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then as needed for one week's duration.
Patient allocated to the control group will be discharged home with a prescription for regular acetaminophen, naproxen, and 5 tabs of hydromorphone 1 mg, with instruction to prioritize non opioid analgesic as first line.
Outcomes
Primary Outcome Measures
Pain score on post-operative day one
The primary outcome of this study is patient reported pain using an 11-point Numerical Rating Scale (NRS) on post-operative day two, on a scale from 0 to 10 in which higher scores indicate higher pain (worse pain control).
Secondary Outcome Measures
Patient mobility and satisfaction of analgesia
Patients will receive a phone call on post-operative day one and seven and will be asked a standardised set of questions binary question (Yes / No) to evaluate patient mobility and satisfaction of analgesia.
Total narcotic consumption in the first post-operative week
Patients will receive a phone call on post-operative day one and seven and will be asked total amount of narcotic consumed since discharge from the hospital, including need for rescue prescription
Opioid related side effect
Patients will receive a phone call on post-operative day one and seven and will be inquired about specific opioid side effect.
Unplanned return to emergency room / clinic
Patients will receive a phone call on post-operative day one and seven and will be inquired about any unplanned visit to emergency room / clinic since discharged from the hospital.
Overall satisfaction with pain control
Patients will receive a phone call on post-operative day one and seven and will be asked about overall satisfaction with pain control via standardised questionnaire.
Pain score on post-operative day one
Patient reported pain using an 11-point Numerical Rating Scale (NRS) on post-operative day one, on a scale from 0 to 10 in which higher scores indicate higher pain (worse pain control).
Full Information
NCT ID
NCT04837014
First Posted
April 5, 2021
Last Updated
September 12, 2023
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
1. Study Identification
Unique Protocol Identification Number
NCT04837014
Brief Title
Eliminating Narcotic Prescriptions From Outpatient Minimally Invasive Gynecologic Surgery
Acronym
eNARCOS
Official Title
Eliminating Narcotic Prescriptions From Outpatient Minimally Invasive Gynecologic Surgery: a Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 4, 2022 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Laparoscopic gynecologic surgeries are generally very well tolerated procedures, and patients are able to go home on the same day, with a prescription for pain control. There is currently a very wide range of prescription practice within the gynecology community in regards to opioids following surgery, and patients are going home with anything from zero to 5 or even 20 tabs of narcotics.
Aside from negative side effect of opioids (like nausea/vomiting, dizziness, constipation, and possibly addiction), unnecessary opioid prescriptions and excess unused narcotics is one of the major contributors to narcotic abuse in the community, worsening an ongoing nationwide opioid crisis. Although most patients report low pain level following these kinds of procedure, there are no current standard prescriptions after gynecologic laparoscopy.
In an effort to standardize discharge prescriptions following gynecologic laparoscopy, this study aims to find an optimal regimen for pain control in the post-operative period following laparoscopic gynecologic surgery. There will be 2 standardized set of discharge prescriptions to which patient will be randomized; both containing multimodal medications for pain control. Pain control, and patients satisfaction will be measured in the first post-operative week.
Detailed Description
Narcotic prescribing patterns vary greatly among gynecologists performing minimally invasive gynecologic surgery (MIGS). There is no clear consensus or established guideline regarding the choice of narcotic or total amount to be prescribed, if any, for MIGS. These represent a generally well-tolerated group of procedures that are less painful than conventional open surgery. Unnecessary opioid prescriptions and excess unused narcotics have been identified as major contributors to narcotic abuse in the community, and efforts geared towards minimizing unnecessary narcotic prescriptions may help curb the growing opioid crisis.
This study suggests eliminating opioids from discharge prescriptions following outpatient MIGS in select patients. Given the general tolerability and low pain associated with MIGS, the investigators hypothesize that elimination of narcotics from post-operative pain control, in conjunction with regular use of non-narcotic analgesics, will result in analgesia and early recovery that is no worse than a standard narcotic-containing discharge prescription.
Women undergoing elective outpatient laparoscopic gynecologic surgery at two medical center associated with the McGill University Health Centre will be recruited and screened for exclusion criteria. Patients will be randomly allocated to either intervention or control groups in a one to one fashion. Patients in both intervention and control group will undergo surgery under a standardized anesthesia protocol. Important surgical steps that can affect post-operative pain will be standardised and recorded with a surgical checklist to reduce inter-surgeon variability. Patient allocated to the intervention arm will then be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then as needed for one week's duration. Patient in control group will be discharge with a standard prescription of five tabs of 1 mg hydromorphone, with regular non-opioid analgesic use.
All patient will be contacted on day one and seven after surgery to evaluate pain scores, mobility, adequacy of analgesia, adherence to treatment, side-effects, and total opioid consumption.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Postoperative, Opioid Use
Keywords
Gynecology, Minimally invasive surgery, Laparoscopy
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
In this randomized controlled trial, consented patient will be randomly allocated to either intervention or control groups in a 1:1 fashion. Allocation will be determined by a computerized randomization generator with block randomization in groups of four. Allocations will be placed in sequentially numbered, sealed, opaque envelopes to be opened only upon completion of surgery of consenting patients.
Masking
InvestigatorOutcomes Assessor
Masking Description
Although the patient and operative team will not be blinded to the allocation, the research team member completing the post-operative questionnaires as well as the statistician responsible for data analysis will remain blinded to the allocation.
Allocation
Randomized
Enrollment
88 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Acetaminophen and naproxen only arm
Arm Type
Experimental
Arm Description
Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then as needed for one week's duration.
Arm Title
Acetaminophen, naproxen and dilaudid arm
Arm Type
Active Comparator
Arm Description
Patient allocated to the control group will be discharged home with a prescription for regular acetaminophen, naproxen, and 5 tabs of hydromorphone 1 mg, with instruction to prioritize non opioid analgesic as first line.
Intervention Type
Other
Intervention Name(s)
prescription for regular acetaminophen and naproxen
Intervention Description
Patient allocated to the intervention arm will be discharged home with a prescription for regular acetaminophen and naproxen for 48 hours, and then prn for one week's duration. No narcotic will be prescribed at discharge post-operatively.
Intervention Type
Other
Intervention Name(s)
prescription for regular acetaminophen , naproxen and dilaudid
Intervention Description
prescription for regular acetaminophen , naproxen and dilaudid
Primary Outcome Measure Information:
Title
Pain score on post-operative day one
Description
The primary outcome of this study is patient reported pain using an 11-point Numerical Rating Scale (NRS) on post-operative day two, on a scale from 0 to 10 in which higher scores indicate higher pain (worse pain control).
Time Frame
Post-operative day one
Secondary Outcome Measure Information:
Title
Patient mobility and satisfaction of analgesia
Description
Patients will receive a phone call on post-operative day one and seven and will be asked a standardised set of questions binary question (Yes / No) to evaluate patient mobility and satisfaction of analgesia.
Time Frame
Post-operative day one and seven
Title
Total narcotic consumption in the first post-operative week
Description
Patients will receive a phone call on post-operative day one and seven and will be asked total amount of narcotic consumed since discharge from the hospital, including need for rescue prescription
Time Frame
Post-operative day seven
Title
Opioid related side effect
Description
Patients will receive a phone call on post-operative day one and seven and will be inquired about specific opioid side effect.
Time Frame
First post-operative week (Day 7)
Title
Unplanned return to emergency room / clinic
Description
Patients will receive a phone call on post-operative day one and seven and will be inquired about any unplanned visit to emergency room / clinic since discharged from the hospital.
Time Frame
First post-operative week (Day 7)
Title
Overall satisfaction with pain control
Description
Patients will receive a phone call on post-operative day one and seven and will be asked about overall satisfaction with pain control via standardised questionnaire.
Time Frame
First post-operative week (Day 7)
Title
Pain score on post-operative day one
Description
Patient reported pain using an 11-point Numerical Rating Scale (NRS) on post-operative day one, on a scale from 0 to 10 in which higher scores indicate higher pain (worse pain control).
Time Frame
Post-operative day 7
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Women undergoing elective outpatient gynecologic laparoscopy
Able to provide informed consent
Planned for same day discharge
Exclusion Criteria:
Chronic pain conditions including, but not limited to: chronic pelvic pain, fibromyalgia, connective tissue disorders, migraines on medication, severe osteoarthritis, sciatica, degenerative disk disease
Regular use of analgesia or narcotics. Defined as use of pain medication on most days of the week, most weeks of the month
History of substance abuse (opioid addiction, IV drug use, etc.)
Known depression or anxiety conditions with or without medication
Eastern Cooperative Oncology Group (ECOG) performance status 3 or greater
Current or recent use of pain modulators such as pregabalin or gabapentin (one month pre-operatively).
Allergy or contraindication to acetaminophen or NSAIDs or hydromorphone/narcotics
Intraoperative complications :
Conversion to laparotomy or mini-laparotomy > 4 cm
Intra-operative gastrointestinal or urologic injury
Intra-operative hemorrhage or need for blood transfusion
Need for admission
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Andrew Zakhari, M.D.
Phone
5142288889
Email
andrew.zakhari@mcgill.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Jade Desilets, M.D.
Phone
5143583147
Email
jade.desilets@mail.mcgill.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew Zakhari, M.D.
Organizational Affiliation
McGill University Health Centre/Research Institute of the McGill University Health Centre
Official's Role
Principal Investigator
Facility Information:
Facility Name
McGill University Health Center
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Zakhari, M.D.
Phone
(514) 228-8889
Email
andrew.zakhari@mcgill.ca
First Name & Middle Initial & Last Name & Degree
Andrew Zakhari, M.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Eliminating Narcotic Prescriptions From Outpatient Minimally Invasive Gynecologic Surgery
We'll reach out to this number within 24 hrs